Associations - sirolimus

No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2
MYCN positive	Neuroblastoma	MYCN positive	Neuroblastoma	dasatinib + temozolomide + sirolimus Sensitive: C3 – Early Trials dasatinib + temozolomide + sirolimus Sensitive : C3	dasatinib + temozolomide + sirolimus Sensitive: C3 – Early Trials dasatinib + temozolomide + sirolimus Sensitive : C3
PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	PIK3CA mutation + HR positive	HER2 Positive Breast Cancer	sirolimus + inetetamab Sensitive: C4 – Case Studies sirolimus + inetetamab Sensitive : C4	sirolimus + inetetamab Sensitive: C4 – Case Studies sirolimus + inetetamab Sensitive : C4
NCOR1-LYN fusion	B Acute Lymphoblastic Leukemia	NCOR1-LYN fusion	B Acute Lymphoblastic Leukemia	sirolimus Resistant: D – Preclinical sirolimus Resistant : D	sirolimus Resistant: D – Preclinical sirolimus Resistant : D
KRAS G12D + TP53 deletion	Lung Adenocarcinoma	KRAS G12D + TP53 deletion	Lung Adenocarcinoma	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
STK11 mutation	Non Small Cell Lung Cancer	STK11 mutation	Non Small Cell Lung Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
NOTCH1 expression	Acute Lymphocytic Leukemia	NOTCH1 expression	Acute Lymphocytic Leukemia	sirolimus + MRK003 Sensitive: D – Preclinical sirolimus + MRK003 Sensitive : D	sirolimus + MRK003 Sensitive: D – Preclinical sirolimus + MRK003 Sensitive : D
TP53 deletion	Colorectal Cancer	TP53 deletion	Colorectal Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
MTOR F2108L	Thyroid Gland Carcinoma	MTOR F2108L	Thyroid Gland Carcinoma	sirolimus Resistant: D – Preclinical sirolimus Resistant : D	sirolimus Resistant: D – Preclinical sirolimus Resistant : D
TP53 deletion	Non Small Cell Lung Cancer	TP53 deletion	Non Small Cell Lung Cancer	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D	sirolimus + IPI-504 Sensitive: D – Preclinical sirolimus + IPI-504 Sensitive : D
EPHA2 G391R	Non Small Cell Lung Cancer	EPHA2 G391R	Non Small Cell Lung Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
ROR1 expression	Cervical Cancer	ROR1 expression	Cervical Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
JAK2 R683G	Acute Lymphocytic Leukemia	JAK2 R683G	Acute Lymphocytic Leukemia	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
TP53 mutation	Medulloblastoma	TP53 mutation	Medulloblastoma	AN2025 + sirolimus Sensitive: D – Preclinical AN2025 + sirolimus Sensitive : D	AN2025 + sirolimus Sensitive: D – Preclinical AN2025 + sirolimus Sensitive : D
GNA13 deletion + KRAS mutation	Pancreatic Cancer	GNA13 deletion + KRAS mutation	Pancreatic Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
KRAS mutation + TP53 mutation + GNA13 deletion	Pancreatic Cancer	KRAS mutation + TP53 mutation + GNA13 deletion	Pancreatic Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D
GNA13 deletion + TP53 mutation	Pancreatic Cancer	GNA13 deletion + TP53 mutation	Pancreatic Cancer	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D	sirolimus Sensitive: D – Preclinical sirolimus Sensitive : D

sirolimus

Associations
(20)

Associations
(20)

sirolimus

Associations(20)

Associations(20)

Associations
(20)

Associations
(20)